DR 2313

Modify Date: 2024-01-09 16:49:49

DR 2313 Structure
DR 2313 structure
Common Name DR 2313
CAS Number 284028-90-6 Molecular Weight 182.243
Density 1.5±0.1 g/cm3 Boiling Point 349.3±52.0 °C at 760 mmHg
Molecular Formula C8H10N2OS Melting Point N/A
MSDS USA Flash Point 165.0±30.7 °C

 Use of DR 2313


DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2].

 Names

Name 7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one
Synonym More Synonyms

 DR 2313 Biological Activity

Description DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2].
Related Catalog
Target

PARP-1:0.20 μM (IC50)

PARP-2:0.24 μM (IC50)

In Vitro DR2313 (0.016-16.4 μM; 30 min) inhibits poly(ADP-ribosyl)ation reaction in nuclear extracts of rat brain, with a Ki of 0.23 μM[1]. DR2313 shows more powerful inhibition of the poly(ADP-ribosyl)ation in the nuclear extracts of the rat brain (IC50=0.20 μM) than 3AB (35.4 μM), PND (0.56 μM), DIQ (2.96 μM), and DPQ (0.96 μM)[1]. DR2313 (1-100 μM; 10 min) shows a weak inhibition of the mono(ADP-ribosyl)ation in a concentration-dependent manner (IC50=59 μM)[1]. DR2313 (0.1-30 μM; pretreated for 30 min) reduces hydrogen peroxide (500 μM; 4 h) or glutamate (1 mM; 30 min) induced excessive formation of poly(ADP-ribose) and cell death[1].
In Vivo DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats[1]. Animal Model: Male Wistar rats (220-300 g) with permanent MCA occlusions (pMCAos) and transient MCA occlusions (tMCAos)[1] Dosage: 3, 10 mg/kg Administration: I.v. bolus and i.v. infusion for 6 h beginning 5 min before the onset of ischemia Result: Reduced the infarct volume in a dose-dependent manner in pMCAo and tMCAo model.
References

[1]. Nakajima H, et, al. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81.

[2]. Xu Z, et, al. Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R215-21.

 Chemical & Physical Properties

Density 1.5±0.1 g/cm3
Boiling Point 349.3±52.0 °C at 760 mmHg
Molecular Formula C8H10N2OS
Molecular Weight 182.243
Flash Point 165.0±30.7 °C
Exact Mass 182.051376
PSA 71.05000
LogP 0.66
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.714
Storage condition 2~8°C

 Safety Information

Hazard Codes Xn
RIDADR NONH for all modes of transport
HS Code 2934999090

 Customs

HS Code 2934999090
Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Synonyms

2-Methyl-1,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one
3,5,7,8-Tetrahydro-2-methyl-4H-thiopyrano[4,3-d]pyrimidin-4-one
2-methyl-3,5,7,8-tetrahydrothiopyrano(4,3-d)pyrimidine-4-one
7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one
4H-Thiopyrano[4,3-d]pyrimidin-4-one, 1,5,7,8-tetrahydro-2-methyl-
DR 2313
1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE
2-Methyl-1-sulfanyl-1H,4H,5H,7H,8H-pyrano[4,3-d]pyriMidin-4-one
3,5,7,8-tetrahydro-2-methyl-4h-thiopyrano(4,3-d)pyrimidin-4-one
Top Suppliers:I want be here





Get all suppliers and price by the below link:

DR 2313 suppliers


Price: ¥600/5 mg

Reference only. check more DR 2313 price

Related Compounds: More...
9-acetyl-12-amino-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9-dihydroxy-4-methoxy-7,8,10,12-tetrahydrotetracen-5-one
123618-01-9
ethyl (E)-3-[[(2S,3S,4S,6R)-6-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]amino]but-2-enoate
107701-62-2
3a,7-Epoxy-3aH-furo(3,2-b)oxocin-3-carboxylic acid,5-(6-(2,5-dihydro-4-hydroxy-2-oxo-1H-pyrrol-3-yl)-1,3-dimethyl-6-oxo-2,4-hexadienyl)octahydro-2,6,9a-trimethyl-8-oxo-,methyl ester
69774-87-4
K-DR
272776-87-1
3-(Dr-1tF,2cF,3rF,4-tetrahydroxy-but-catF-yl)-1H-quinoxalin-2-one
1222-71-5
WSQR DR
2113-68-0
DR4485 hydrochloride
402942-53-4
D-Ofloxacin
100986-86-5
methyl 5-((3E,5E,7E)-7-hydroxy-4-methyl-7-(1-methyl-2,4-dioxopyrrolidin-3-ylidene)hepta-3,5-dien-2-yl)-2,6,9a-trimethyl-8-oxooctahydro-3a,7-epoxyfuro[3,2-b]oxocine-3-carboxylate
69774-86-3
Tert-butyl 4-(5-bromo-2-chloropyridin-3-yl)piperazine-1-carboxylate
2749841-53-8
Dicresulene Disodium Salt
79093-74-6
tert-butyl N-[4-(1H-imidazol-4-yl)cyclohexyl]carbamate
1354280-36-6
2-[2-(Dimethylamino)ethoxy]-9H-fluoren-9-one Hydrochloride
3254-87-3
2-(3,3-Dimethylcyclobutyl)ethan-1-OL
2284762-68-9
1-[2-Deoxy-3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-beta-D-erythro-pentofuranosyl]-1H-1,2,4-triazole-3-carboxamide
359861-06-6
4-(1-Aminobutyl)-2-phenylphenol
2172015-18-6
5-chloro-2-fluoro-3-(1-methyl-1H-pyrazol-4-yl)pyridine
2137674-74-7
1-(4-bromo-2-chlorophenyl)-3-methyl-2-Pyrrolidinone
2882834-04-8
8-(Benzyloxy)-1-oxaspiro[4.5]decan-3-amine
2882170-64-9